Literature DB >> 20541028

Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.

Philipp Yorck Herzberg1, Pia Heussner, Friederike H A Mumm, Melanie Horak, Inken Hilgendorf, Stephanie von Harsdorf, Philipp Hemmati, Kathrin Rieger, Hildegard Greinix, Mathias Freund, Stephanie J Lee, Ernst Holler, Daniel Wolff.   

Abstract

Chronic graft-versus-host disease (cGVHD) associated morbidity and mortality remain major barriers for successful allogeneic hematopoietic stem cell transplantation (alloHSCT). Currently, no reliable measures are established to monitor cGVHD activity changes for use in clinical trials. The Human Activity Profile (HAP) patient self-report was proposed by the National Institutes of Health (NIH) cGVHD consensus project as an independent measure of patients' functional status that could also indirectly reflect improvement of cGVHD, but that has not been validated in an alloHSCT patient population. One hundred seventy-six patients (median age 44 years [range: 18-72 years] after alloHSCT were evaluated with a German translation of the HAP, the NIH criteria-based cGVHD activity assessment, the Lee cGVHD Symptom-Scale, FACT-BMT, SF36, Berlin Social Support Scale, 24-Item Adjective Measure (24-AM), Hospital Anxiety and Depression Scale, and the NCCN-Distress-Thermometer. Enrollment occurred a median of 286 (range: 85-4003) days after alloHSCT. Follow-up surveys were conducted at 1, 2, 3, 5, 8, and 12 months after the baseline survey. Although 117 patient had cGVHD at time of enrollment (mild n = 33, moderate n = 50, or severe n = 34), 59 patients were included into the study in the absence of cGVHD between days 85 and 395 after transplantation. The maximum activity score (MAS) and adjusted activity score (AAS) of the HAP correlated inversely with grading of cGVHD severity (mild, moderate, or severe) (r = -0.25 for MAS and -0.24 for AAS). Lung manifestations of cGVHD correlated with AAS (r = 0.17), but not with MAS. HAP scores correlated with subscales from other instruments measuring physical domains, especially the physical functioning scale of the SF36. Performance was improved by use of an HSCT-modified HAP scoring system that excluded activities prohibited within the first year after alloHSCT. No significant correlation of the HAP was found with personality, age, sex, symptom burden, or social functioning or social well-being. Moreover, the HAP displayed a higher sensitivity to change of cGVHD activity compared to the SF36 and the FACT-BMT. In addition, steroid myopathy correlated with both HAP scores, but not the SF36. The HAP is a simple and valid questionnaire for the evaluation of the physical activity in patients after alloHSCT, with the advantage of detecting changes in cGVHD status independently of other quality-of-life measures and with a superior sensitivity compared to the SF36.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541028     DOI: 10.1016/j.bbmt.2010.05.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  41 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease.

Authors:  Christina Slota; Margaret Bevans; Li Yang; Joseph Shrader; Galen Joe; Nuria Carrillo
Journal:  Disabil Rehabil       Date:  2017-02-07       Impact factor: 3.033

3.  Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Joseph Pidala; Xiaoyu Chai; Brenda F Kurland; Daniel Weisdorf; Mary E D Flowers; Jeanne Palmer; Sally Arai; David Jacobsohn; Corey Cutler; Madan Jagasia; Jenna D Goldberg; Paul J Martin; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee; Paul A Carpenter
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

5.  Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life.

Authors:  Yi-Chen Sun; Xiaoyu Chai; Yoshihiro Inamoto; Joseph Pidala; Paul J Martin; Mary E D Flowers; Tueng T Shen; Stephanie J Lee; Madan Jagasia
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-30       Impact factor: 5.742

6.  Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial.

Authors:  Kristin Pulewka; Daniel Wolff; Philipp Y Herzberg; Hildegard Greinix; Pia Heussner; Friederike H A Mumm; Stephanie von Harsdorf; Kathrin Rieger; Philipp Hemmati; Andreas Hochhaus; Inken Hilgendorf
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-19       Impact factor: 4.553

7.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Authors:  N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli
Journal:  Hematol Oncol Stem Cell Ther       Date:  2012

8.  Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Xiaoyu Chai; Paul Martin; Yoshihiro Inamoto; Corey Cutler; Jeanne Palmer; Daniel Weisdorf; Steven Pavletic; Mukta Arora; Madan Jagasia; David Jacobsohn; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-27       Impact factor: 5.742

9.  Malnutrition in patients with chronic GVHD.

Authors:  C W Bassim; H Fassil; M Dobbin; S M Steinberg; K Baird; K Cole; G Joe; L E Comis; S A Mitchell; L Grkovic; D Edwards; J W Mays; E W Cowen; D Pulanic; K M Williams; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-07-14       Impact factor: 5.483

10.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.